The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

Hua-Tao Wu; Jing Liu; Guan-Wu Li; Jia-Xin Shen; Yi-Teng Huang

doi:10.18632/oncotarget.16748

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

Hua-Tao Wu _, Jing Liu, Guan-Wu Li, Jia-Xin Shen and Yi-Teng Huang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:36279-36288. https://doi.org/10.18632/oncotarget.16748

Metrics: PDF 2614 views | HTML 3085 views | ?

Abstract

Hua-Tao Wu1, Jing Liu1,2, Guan-Wu Li3, Jia-Xin Shen4, Yi-Teng Huang5

1Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China

2Chang Jiang Scholar’s Laboratory, Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou University Medical College, Shantou, PR China

3Open Laboratory for Tumor Molecular Biology, Department of Biochemistry, The Key Lab of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, PR China

4Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China

5Health Care Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China

Correspondence to:

Hua-Tao Wu, email: [email protected]

Jing Liu, email: [email protected]

Keywords: STAT, breast carcinoma, prognosis, Kaplan-Meier plot, transcription

Received: December 08, 2016 Accepted: March 21, 2017 Published: March 31, 2017

ABSTRACT

Signal Transducer and Activators of Transcription (STAT) is a set of transcription factors, involved in diverse cellular functions. Evidences from cell lines, mouse models and human tissues implicate these transcription factors in the oncogenesis of breast cancer. However, the diverse expression patterns and prognostic values of 7 STATs remain to be elucidated. In the current study, we mined the transcriptional and survival data of STATs in patients with breast carcinoma (BC) through ONCOMINE, bc-GenExMiner, Kaplan-Meier Plotter and cBioPortal. It was found that STAT1/2 were up-regulated, whereas STAT3/4/5A/5B were down-regulated in BC patients compared with the normal tissues. The expressions of STAT5A/5B/6 were correlated with decreased levels of histological differentiation. In survival analyses through the Kaplan-Meier plotter database, high transcription levels of STAT2/4/5A/5B/6 were associated with better relapse-free survival (RFS) in all BC patients. Conversely, high STAT3 predicted shorter RFS in BC patients, suggesting that STAT3 is potential targets for precision therapy to BC patients. These data also provided STAT5A/5B/6 as new biomarker for BC prognosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16748

Publication Alerts

Research Papers:

The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

Abstract